Your browser is no longer supported. Please, upgrade your browser.
Settings
GLMD Galmed Pharmaceuticals Ltd. daily Stock Chart
GLMD [NASD]
Galmed Pharmaceuticals Ltd.
Index- P/E- EPS (ttm)-0.75 Insider Own21.13% Shs Outstand21.48M Perf Week2.92%
Market Cap128.67M Forward P/E- EPS next Y-1.44 Insider Trans0.00% Shs Float16.60M Perf Month37.07%
Income-15.90M PEG- EPS next Q-0.36 Inst Own36.00% Short Float2.92% Perf Quarter26.11%
Sales0.00M P/S- EPS this Y44.80% Inst Trans-5.81% Short Ratio4.38 Perf Half Y5.46%
Book/sh3.67 P/B1.63 EPS next Y-53.80% ROA-18.40% Target Price30.70 Perf Year-29.53%
Cash/sh3.71 P/C1.61 EPS next 5Y- ROE-19.20% 52W Range3.42 - 9.74 Perf YTD-12.30%
Dividend- P/FCF- EPS past 5Y20.60% ROI-12.30% 52W High-38.50% Beta2.80
Dividend %- Quick Ratio22.80 Sales past 5Y- Gross Margin- 52W Low75.25% ATR0.56
Employees17 Current Ratio22.80 Sales Q/Q- Oper. Margin- RSI (14)64.68 Volatility15.71% 9.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-366.90% Profit Margin- Rel Volume1.61 Prev Close6.50
ShortableYes LT Debt/Eq0.00 EarningsNov 06 BMO Payout- Avg Volume110.47K Price5.99
Recom1.80 SMA2021.61% SMA5035.36% SMA200-2.38% Volume178,142 Change-7.85%
Dec-02-19Initiated Canaccord Genuity Buy
Dec-12-18Initiated B. Riley FBR Buy $28
Aug-02-18Reiterated Maxim Group Buy $30 → $27
Jul-13-18Initiated Stifel Buy $35
Jul-12-18Initiated Cantor Fitzgerald Overweight $59
Jun-12-18Reiterated H.C. Wainwright Buy $24 → $43
Mar-15-18Upgrade Maxim Group Hold → Buy $14
Feb-14-18Downgrade Maxim Group Buy → Hold
Feb-12-18Reiterated H.C. Wainwright Buy $18 → $24
Nov-15-17Initiated ROTH Capital Buy $32
Aug-08-17Reiterated H.C. Wainwright Buy $12 → $18
Jul-31-17Reiterated Maxim Group Buy $9 → $14
Aug-01-16Reiterated Maxim Group Buy $24 → $9
Jul-06-16Resumed ROTH Capital Buy $6
Mar-28-16Resumed H.C. Wainwright Buy $22
Jun-23-15Initiated H.C. Wainwright Buy $21
May-06-15Initiated Sun Trust Rbsn Humphrey Buy $20
Apr-15-15Initiated ROTH Capital Buy $20
Sep-24-14Reiterated MLV & Co Buy $19 → $24
May-09-14Initiated MLV & Co Buy $19
Dec-04-19 09:26AM  Top Ranked Momentum Stocks to Buy for December 4th Zacks +18.42%
Nov-29-19 08:41AM  NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-08-19 10:57PM  Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-06-19 07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results PR Newswire -10.11%
Nov-04-19 09:10AM  Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 60% Simply Wall St. +5.26%
Oct-31-19 08:30AM  Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 PR Newswire +13.11%
Oct-30-19 08:30AM  Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6 PR Newswire
Sep-26-19 08:00AM  Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis PR Newswire
Sep-19-19 01:05PM  Should You Buy Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) For This Reason? Simply Wall St. +7.87%
Aug-12-19 04:33AM  Edited Transcript of GLMD earnings conference call or presentation 5-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results PR Newswire -13.76%
Jul-29-19 08:30AM  Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5 PR Newswire
Jul-24-19 01:17PM  Could The Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ownership Structure Tell Us Something Useful? Simply Wall St. +7.43%
May-23-19 12:37PM  Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Being Overpaid? Simply Wall St.
May-07-19 08:25AM  Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates Zacks -5.45%
07:21AM  Galmed Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results PR Newswire
Apr-30-19 08:30AM  Galmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7 PR Newswire
Apr-09-19 07:30AM  Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3 PR Newswire
Mar-13-19 08:25AM  Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:00AM  Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update PR Newswire
Mar-12-19 10:02AM  Update: Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Gained 95% In The Last Three Years Simply Wall St.
08:00AM  Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol PR Newswire
Mar-06-19 08:30AM  Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13 PR Newswire -5.04%
Dec-28-18 04:52PM  Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018 Zacks
Dec-12-18 02:26PM  What does Galmed Pharmaceuticals Ltd.s (NASDAQ:GLMD) Balance Sheet Tell Us About Its Future? Simply Wall St. +18.56%
Dec-11-18 09:22AM  Novan Announces Top-Line Data From Mid-Stage Molluscum Study Zacks -5.38%
Nov-20-18 08:45AM  Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher Zacks -5.48%
Nov-14-18 07:50AM  Recent Analysis Shows COUPA SOFTWARE, Galmed Pharmaceuticals, Sunworks, Murphy, Diversicare Healthcare Services, and Pro-Dex Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-13-18 11:30AM  Phase 2 Data for Galmed Pharmaceutical's Aramchol in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018 PR Newswire -7.01%
04:02AM  Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-05-18 08:45AM  Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.37%
07:39AM  Galmed Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results PR Newswire
Oct-31-18 03:38PM  Nantahala Capital Managements Returns, AUM, and Holdings Insider Monkey
Oct-29-18 08:30AM  Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5 PR Newswire
Oct-12-18 03:21PM  Who Really Owns Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)? Simply Wall St.
Oct-02-18 08:39AM  Galmed Pharmaceuticals Announces a Late-Breaking Abstract on Aramchol to be Presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® PR Newswire +5.47%
Sep-27-18 08:00AM  Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference PR Newswire
Aug-02-18 05:40PM  Medical-Drugs Stock Outlook: No Respite from Near-Term Pain Zacks
10:55AM  Galmed Pharmaceuticals (GLMD) Reports Q2 Loss Zacks
09:51AM  Galmed Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results PR Newswire
Jul-26-18 08:30AM  Galmed Pharmaceuticals to Report Second Quarter 2018 Financial Results and Provide Business Update on Thursday, August 2 PR Newswire
Jul-20-18 11:42AM  What's in Store for Universal Health's (UHS) Q2 Earnings? Zacks
11:26AM  What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings? Zacks
Jul-13-18 07:02PM  Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week Motley Fool +19.34%
10:49AM  Galmed Notches Second Bullish Rating On Aramchol Opportunity Benzinga
08:00AM  Today's Research Reports on Stocks to Watch: Galmed Pharmaceuticals and Zogenix ACCESSWIRE
Jul-12-18 12:11PM  Cantor Fitzgerald Makes An Uber-Bullish Call On Galmed Pharmaceuticals Benzinga +21.04%
08:00AM  Today's Research Reports on Trending Tickers: Galmed Pharmaceuticals and Akcea Therapeutics ACCESSWIRE
Jun-26-18 07:06AM  This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It Motley Fool
Jun-25-18 07:30AM  Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock ACCESSWIRE
Jun-20-18 08:36AM  Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading Benzinga -9.43%
Jun-19-18 09:37PM  Galmed Pharmaceuticals Ltd. Announces Pricing of Public Offering of Ordinary Shares PR Newswire +5.23%
Jun-18-18 06:30AM  Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares PR Newswire -9.09%
Jun-16-18 07:18AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-15-18 09:27AM  Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals Zacks
08:07AM  3 NASH Stocks That Could Soar in the Second Half of 2018 Motley Fool
07:40AM  Hacking the Human Brain: This Unknown Stock (With 1 Very Prominent Shareholder) Could Change The Game & Make Shareholders Unheard of Returns ACCESSWIRE
Jun-14-18 10:30AM  Are These Red-Hot NASH Stocks Still a Buy? Motley Fool -10.58%
09:23AM  NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
Jun-13-18 09:43AM  Galmed (GLMD) Soars on Positive NASH Data on Aramchol Zacks
08:15AM  Comprehensive Research Report, Galmed Pharmaceuticals Soars on Clinical Trial Results in Liver Disease Study ACCESSWIRE
08:00AM  Todays Research Reports on Stocks to Watch: Sage Therapeutics and Galmed Pharmaceuticals ACCESSWIRE
Jun-12-18 12:37PM  Why Galmed Pharmaceuticals Ltd Stock Is Going Gangbusters Today InvestorPlace +151.29%
11:23AM  Galmed's 200% Jump Leads Biotechs Higher Barrons.com
10:37AM  Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today Motley Fool
08:47AM  Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate Benzinga
08:36AM  Galmed Pharmaceuticals' stock rockets 161% after trial results support FDA marketing application MarketWatch
08:15AM  Israeli company Galmed gets positive trial results for liver drug Reuters
07:00AM  Galmed's 600 mg Aramchol Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study PR Newswire
Jun-11-18 04:30PM  Galmed Pharmaceuticals to Host Conference Call to Discuss Top-Line, 52-Week Results from the Global Phase 2b ARREST Study PR Newswire
May-14-18 10:11AM  Whats Ahead For Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)? Simply Wall St.
May-11-18 05:31PM  What You Must Know About Galmed Pharmaceuticals Ltds (NASDAQ:GLMD) Market Risks Simply Wall St.
May-09-18 07:21AM  Galmed Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results PR Newswire
May-02-18 08:18PM  Has Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Improved Earnings Growth In Recent Times? Simply Wall St.
May-01-18 08:00AM  Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9 PR Newswire
Apr-20-18 05:06PM  What Are Analysts Expecting From Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Over The Next Few Years? Simply Wall St.
Apr-16-18 07:00AM  Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol for NASH PR Newswire
Apr-11-18 08:00AM  InMed Announces Appointment of Joshua Blacher as Chief Business Officer CNW Group
Apr-03-18 07:00AM  Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering PR Newswire +15.08%
Mar-27-18 07:00AM  Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL PR Newswire -12.63%
Mar-15-18 01:12PM  Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade Benzinga +6.95%
Mar-13-18 07:30AM  Galmed Pharmaceuticals reports 4Q loss Associated Press
07:05AM  Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update PR Newswire
06:30AM  Galmed Pharmaceuticals Ltd. to Host Earnings Call ACCESSWIRE
Mar-05-18 07:00AM  Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13 PR Newswire
Mar-02-18 07:00AM  Galmed Pharmaceuticals to Participate in Investor Conferences in March PR Newswire
Feb-28-18 07:15PM  Galmed Pharmaceuticals Ltds (NASDAQ:GLMD) Path To Profitability Simply Wall St.
Feb-14-18 09:15AM  Galmed Pharma's stock loses more than half its value after drug trial misses endpoint MarketWatch -42.39%
07:00AM  Galmed Announces ARRIVE Study Data PR Newswire
Feb-08-18 07:00AM  Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire
Feb-07-18 09:08AM  Galmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits PR Newswire
Jan-02-18 07:00AM  Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017 PR Newswire
Dec-26-17 05:08PM  7 Stocks Moving In Tuesday's After-Hours Session Benzinga
Dec-18-17 08:15PM  Galmed Pharmaceuticals Ltd (NASDAQ:GLMD): Financial Strength Analysis Simply Wall St.
Nov-29-17 08:21AM  Galmed Pharmaceuticals Ltd. :GLMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 07:00AM  Galmed Pharmaceuticals to Present at HEP DART 2017 Meeting PR Newswire
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.